(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 February 2010 (25.02.2010)

PCT

(10) International Publication Number
WO 2010/020610 A1

(51) International Patent Classification:
A61K 31/397 (2006.01) *A61K 31/42* (2006.01)
A61K 31/452 (2006.01) *A61K 31/436* (2006.01)
A61P 25/00 (2006.01) *A61K 31/519* (2006.01)
A61K 31/16 (2006.01) *A61K 31/52* (2006.01)
A61K 31/195 (2006.01) *A61K 31/56* (2006.01)
A61K 31/34 (2006.01) *A61K 31/675* (2006.01)
A61K 31/401 (2006.01) *A61K 38/13* (2006.01)
A61K 31/417 (2006.01)

(21) International Application Number:
PCT/EP2009/060611

(22) International Filing Date:
17 August 2009 (17.08.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
08162517.0 18 August 2008 (18.08.2008) EP

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LEPPERT, David** [CH/CH]; Auf der Wacht 13, CH-4104 Oberwil (CH). **WALLSTROEM, Erik** [SE/CH]; Margarethenstrasse 48, CH-4102 Binningen (CH). **NUESSLEIN-HILDESHEIM, Barbara** [DE/DE]; Markgrafenstrasse 15, 79591 Eimeldigen (DE).

(74) Agent: **JEFFRIES, Charles**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,

[Continued on next page]

(54) Title: COMPOUNDS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES




Figure 1A – Neurological score vs no. of days after immunisation for EAN rats treated with water vehicle (group 1) and CMC vehicle (group 2).






Figure 1B - Neurological score vs no. of days after immunisation for EAN rats treated with 3mg/kg compound A suspension (group 5) and 10 mg/kg compound A suspension (group 6).





(57) Abstract: A compound of formula A1 or A2 for use in the treatment of a demyelinating peripheral neuropathy: wherein A is $COOR_5$, $OPO(OR_5)_2$, $PO(OR_5)_2$, SO_2OR_5, POR_5OR_5 or 1*H*-tetrazol-5-yl, R_5 being H or an ester-forming group, optionally C_{1-6}alkyl; W is a bond, C_{1-3}alkylene or C_{2-3}alkenylene; Y is C_{6-10}aryl or C_{2-9}heteroaryl eg C_{3-9}heteroaryl, optionally substituted by 1 to 3 radicals selected from halogen, OH, NO_2, C_{1-6}alkyl, C_{1-6}alkoxy; halo-substituted C_{1-6}alkyl and halo-substituted C_{1-6}alkoxy; Z is chosen from Formula (I) : wherein the asterisks of Z indicate the point of attachment between $-C(R_3)(R_4)-$ and A of Formula (Ia) or (Ib), respectively; R_6 is chosen from hydrogen and C_{1-6}alkyl; and J_1 and J_2 are independently methylene or a heteroatom chosen from S, O and NR_5; wherein R_5 is chosen from hydrogen and C_{1-6}alkyl; and any alkylene of Z can be further substituted by one to three radicals chosen from halo, hydroxy, C_{1-6}alkyl; or R_6 can be attached to a carbon atom of Y to form a 5-7 member ring; R_1 is C_{6-10}aryl or C_{2-9}heteroaryl eg C_{3-9}heteroaryl, optionally substituted by C_{1-6}alkyl, C_{6-10}aryl, C_{6-10}arylC_{1-4}alkyl, C_{3-9}heteroaryl, C_{3-9}heteroarylC_{1-4}alkyl, C_{3-8}cycloalkyl, C_{3-8}cycloalkylC_{1-4}alkyl, C_{3-8}heterocycloalkyl or C_{3-8}heterocycloalkylC_{1-4}alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_1 may be substituted by 1 to 5 groups selected from halogen, C_{1-6}alkyl, C_{1-6}alkoxy and halo substituted-C_{1-6}alkyl or -C_{1-6}alkoxy; R_2 is H, C_{1-6}alkyl, halo substituted C_{1-6}alkyl, C_{2-6}alkenyl or C_{2-6}alkynyl; and each of R_3 and R_4, independently, is H, halogen, OH, C_{1-6}alkyl, C_{1-6}alkoxy or halo substituted C_{1-6}alkyl or C_{1-6}alkoxy; and the N-oxide derivatives thereof or prodrugs thereof, or a pharmacologically acceptable salt, solvate or hydrate thereof.

WO 2010/020610 A1

SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*